Molecular Profiling Is Rather Likely to Be Cost Effective

Valesca P. Retel*, Sabine C. Linn, Wim H. van Harten

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)1626-627
Number of pages2
JournalJournal of Clinical Oncology
Volume33
Issue number14
DOIs
Publication statusPublished - 10 May 2015

Keywords

  • POSITIVE BREAST-CANCER
  • PHASE-III
  • GUIDELINES
  • SIGNATURE
  • TRIAL

Cite this